We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
76
DELISTED
Centessa Pharmaceuticals
CNTA
$5.49M 0.03%
1,127,273
– –
NKTX icon
77
Nkarta
NKTX
$191M
$4.93M 0.03%
+400,000
New +$5.25M
VERA icon
78
Vera Therapeutics
VERA
$2.33B
$4.54M 0.03%
333,333
– –
RVMD icon
79
Revolution Medicines
RVMD
$44.9B
$4.33M 0.02%
222,222
– –
EWTX icon
80
Edgewise Therapeutics
EWTX
$4.8B
$3.98M 0.02%
500,000
– –
NGNE icon
81
Neurogene
NGNE
$773M
$3.94M 0.02%
191,087
– –
HOOK
82
DELISTED
HOOKIPA Pharma
HOOK
$3.91M 0.02%
240,048
– –
NTRA icon
83
Natera
NTRA
$47.9B
$3.54M 0.02%
+100,000
New +$3.7M
TNGX icon
84
Tango Therapeutics
TNGX
$4.03B
$3.4M 0.02%
750,000
– –
LONA
85
LeonaBio Inc
LONA
$72.4M
$3.17M 0.02%
104,083
+23,446
+29% +$2.15M
ITOS
86
DELISTED
iTeos Therapeutics
ITOS
$3.1M 0.02%
150,346
– –
EVFM
87
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$2.92M 0.02%
+2,583,616
New +$4.26M
MGNX icon
88
MacroGenics
MGNX
$261M
$2.63M 0.01%
892,579
+450,000
+102% +$2.37M
ALGS icon
89
Aligos Therapeutics
ALGS
$41.7M
$2.51M 0.01%
83,056
– –
ALEC icon
90
Alector
ALEC
$264M
$2.43M 0.01%
239,228
– –
BCAB icon
91
BioAtla
BCAB
$5.3M
$2.35M 0.01%
16,500
– –
ALLK
92
DELISTED
Allakos
ALLK
$2.2M 0.01%
703,050
– –
TCRR
93
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.18M 0.01%
753,064
– –
SNDX icon
94
Syndax Pharmaceuticals
SNDX
$1.75B
$2.13M 0.01%
110,729
– –
SYRE icon
95
Spyre Therapeutics
SYRE
$9.39B
$1.72M 0.01%
136,404
– –
EPZM
96
DELISTED
Epizyme, Inc
EPZM
$1.47M 0.01%
1,000,000
– –
AKRO
97
DELISTED
Akero Therapeutics
AKRO
$1.12M 0.01%
118,378
– –
ATYR
98
aTyr Pharma
ATYR
$49.2M
$1.06M 0.01%
374,395
-250,605
-40% -$906K
GTH
99
DELISTED
Genetron Holdings Limited ADS
GTH
$774K ﹤0.01%
151,769
– –
NGM
100
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$709K ﹤0.01%
55,294
-236,507
-81% -$3.28M
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2022 Portfolio in Review

As of Q2 2022, Julian Baker held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Julian Baker added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Julian Baker's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Julian Baker fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Julian Baker's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Julian Baker opened 5 new positions and closed 6 in Q2 2022.
  • Julian Baker's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.